KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Enterprise Value (2016 - 2026)

Fulgent Genetics' Enterprise Value history spans 12 years, with the latest figure at -$282.0 million for Q1 2026.

  • On a quarterly basis, Enterprise Value rose 13.17% to -$282.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$282.0 million, a 13.17% increase, with the full-year FY2025 number at -$341.4 million, down 30.2% from a year prior.
  • Enterprise Value hit -$282.0 million in Q1 2026 for Fulgent Genetics, up from -$341.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for FLGT hit a ceiling of -$216.6 million in Q3 2024 and a floor of -$578.3 million in Q1 2022.
  • Historically, Enterprise Value has averaged -$386.0 million across 5 years, with a median of -$380.9 million in 2025.
  • Biggest five-year swings in Enterprise Value: tumbled 84.84% in 2022 and later skyrocketed 53.38% in 2024.
  • Tracing FLGT's Enterprise Value over 5 years: stood at -$523.0 million in 2022, then increased by 18.37% to -$427.0 million in 2023, then surged by 38.6% to -$262.2 million in 2024, then plummeted by 30.2% to -$341.4 million in 2025, then increased by 17.4% to -$282.0 million in 2026.
  • Business Quant data shows Enterprise Value for FLGT at -$282.0 million in Q1 2026, -$341.4 million in Q4 2025, and -$380.9 million in Q3 2025.